Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Jul;8(14):892.
doi: 10.21037/atm.2020.03.131.

Opicinumab: is it a potential treatment for multiple sclerosis?

Affiliations
Editorial

Opicinumab: is it a potential treatment for multiple sclerosis?

Zubair Ahmed et al. Ann Transl Med. 2020 Jul.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/atm.2020.03.131). The authors have no conflicts of interest to declare.

Comment on

References

    1. Cadavid D, Mellion M, Hupperts R, et al. Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol 2019;18:845-56. 10.1016/S1474-4422(19)30137-1 - DOI - PubMed
    1. Goldenberg MM. Multiple sclerosis review. P T 2012;37:175-84. - PMC - PubMed
    1. Graf J, Aktas O, Rejdak K, et al. Monoclonal Antibodies for Multiple Sclerosis: An Update. BioDrugs 2019;33:61-78. 10.1007/s40259-018-0327-9 - DOI - PubMed
    1. Mi S, Lee X, Shao Z, et al. LINGO-1 is a component of the Nogo-66 receptor/p75 signaling complex. Nat Neurosci 2004;7:221-8. 10.1038/nn1188 - DOI - PubMed
    1. Ahmed Z, Douglas MR, John G, et al. AMIGO3 is an NgR1/p75 co-receptor signalling axon growth inhibition in the acute phase of adult central nervous system injury. PLoS One 2013;8:e61878. 10.1371/journal.pone.0061878 - DOI - PMC - PubMed